Recent Happenings
OTD Launches Inventors Recognition Program
The Office of Technology Development (OTD) recently launched a new program to recognize NIAID inventors for their contributions to successful technology transfer at NIH. NIAID Patent Awards are triggered when the U.S. Patent and Trademark Office decides a NIAID patent application should mature from “patent pending” status to issuance as a U.S. patent. These technologies have withstood the patent application process and been found to be both novel and useful in the legal sense, a process that typically takes several years and many hours of effort by NIAID inventors.
In FY 2011, NIAID recognized the following individuals for their contributions to the U.S. patents listed below (only current NIAID employees are shown).
- United States patent US 7,947,289 was issued on May 24, 2011, for multimeric protein toxins to target cells having multiple identifying characteristics. NIAID inventors: Stephen H. Leppla, Ph.D.; Shihui Liu, M.D., Ph.D.
- United States patent US 7,932,074 was issued on Apr. 26, 2011, for multivalent human-bovine rotavirus vaccine. NIAID inventors: Albert Z. Kapikian, M.D.; Yasutaka Hoshino, D.V.M.
- United States patent US 7,914,788 was issued on Mar. 29, 2011, for monoclonal antibodies against orthopoxviruses. NIAID inventors: Bernard Moss, M.D., Ph.D.; Patricia Earl, Ph.D.; Robert Purcell, M.D.; Suzanne Emerson, Ph.D.; Zhao Chun Chen, Ph.D.
- United States patent US 7,910,105 was issued on Mar. 22, 2011, for methods for treating and preventing fibrosis. NIAID inventor: Thomas Wynn, Ph.D.
- United States patent US 7,820,181 was issued on Oct. 26, 2010, for recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens. NIAID inventors: Brian Murphy, M.D. (retired); Peter Collins, Ph.D.
- United States patent US 7,820,182 was issued on Oct. 26, 2010, for production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions. NIAID inventors: Brian Murphy, M.D. (retired); Peter Collins, Ph.D.; Stephen Whitehead, Ph.D.; Ursula Buchholz, D.V.M., Ph.D.
Recent Patents
United States patent US 8,124,592 was issued on Feb. 28, 2012, for development of a preventive vaccine for filovirus infection in primates. NIAID inventors: Gary J. Nabel, M.D., Ph.D.; Nancy Sullivan, Ph.D.; Zhi-Yong Yang
United States patent US 8,106,026 was issued on Jan. 31, 2012, for development of a preventive vaccine for filovirus infection in primates. NIAID inventors: Gary J. Nabel, M.D., Ph.D.; Nancy Sullivan, Ph.D.; Zhi-Yong Yang
United States patent US 8,106,027 was issued on Jan. 31, 2012, for development of a preventive vaccine for filovirus infection in primates. NIAID inventors: Gary J. Nabel, M.D., Ph.D.; Nancy Sullivan, Ph.D.; Zhi-Yong Yang
United States patent US 8,101,739 was issued on Jan. 24, 2012, for recombinant expression vectors comprising a human codo-optimized Marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector. NIAID inventors: Gary J. Nabel, M.D., Ph.D.; Nancy Sullivan, Ph.D.
United States patent US 8,075,903 was issued on Dec. 13, 2011, for dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4. NIAID inventor: Stephen Whitehead, Ph.D.
United States patent US 8,069,947 was issued on Dec. 6, 2011, for sound attenuation canopy. NIAID inventors: Judit Quasney and David O’Brien
United States patent US 8,071,100 was issued on Dec. 6, 2011, for monoclonal antibodies that neutralize anthrax toxins. NIAID inventors: Robert Purcell, M.D.; Suzanne Emerson, Ph.D.; Stephen Leppla, Ph.D.; Mahtab Moayeri, Ph.D.; Zhaochun Chen, Ph.D.
United States patent US 8,044,185 was issued on Oct. 25, 2011, for conformationally stabilized HIV envelope immunogens, and triggering HIV-1 to reveal cryptic V3-loop epitopes. NIAID inventors: Gary J. Nabel, M.D., Ph.D.; Peter Kwong, Ph.D.; John Mascola, M.D.; Barna Dey, Ph.D.; Tongqing Zhou, Ph.D.; Ling Xu
United States patent US 8,039,003 was issued on Oct. 18, 2011, for development of mutations useful for attenuating dengue viruses and chimeric dengue viruses. NIAID inventor: Stephen Whitehead, Ph.D.
Recent Collaboration Agreements
NIAID and PaxVax, Inc., signed a cooperative research and development agreement (CRADA) under which NIAID will conduct a clinical trial of hemagglutinin 5-based (avian influenza type A) vaccine using a live replication competent recombinant adenovirus, type 4 vector (Ad4-H5-Vtn). NIAID principal investigator: Mark Connors, M.D.
NIAID and Insmed, Inc., have entered into a CRADA to evaluate the efficacy and safety of Arikace (liposomal amikacin for inhalation) in patients with lung infections due to Mycobacterium avium complex (MAC) or Mycobacterium abscessus that have failed to respond to standard, guideline-based treatment regimens. NIAID principal investigator: Steven M. Holland, M.D.
NIAID and Immune Design Corp. have entered into a CRADA under which NIAID will evaluate candidate therapeutic vaccines for herpes simplex virus type 2 infection based on Immune Design’s proprietary toll-like receptor 4 (TLR4) agonist adjuvant. NIAID principal investigator: Jeffrey I. Cohen, M.D.
NIAID and Kansai Medical University Hirakata Hospital signed a research collaboration agreement (RCA) to conduct in vivo tumor xenograph studies with BH3-interacting domain death agonist (BID) overexpression to determine if BID overexpression can become an effective therapy for malignant tumors. NIAID principal investigator: Kathryn C. Zoon, Ph.D.
NIAID and Janssen Research and Development signed an RCA to study the role of anti-IL-23p19 and anti-IL-6 antibodies to study the pathogenesis of colitis. NIAID principal investigator: Brian L. Kelsall, M.D.
NIAID and Guangzhou University of Chinese Medicine signed an RCA to study a number of drugs previously approved for human or animal use against Plasmodium falciparum parasites that have been identified as blocking oocyst development for malaria transmission-blocking activity. NIAID principal investigator: Xin-zhuan Su, Ph.D.
NIAID, Prionics AG, and University of Edinburgh signed an RCA to test the ability of the quaking-induced protein conversion (eQuIC) assay to detect prion protein seeding activity in cerebrospinal fluid from variant Creutzfeldt-Jakob disease patients. NIAID principal investigator: Byron W. Caughey, Ph.D.
NIAID and Emory University signed an RCA to collaborate in the development of optimized broadly neutralizing anti-HIV antibodies. NIAID principal investigator: Gary J. Nabel, M.D., Ph.D.
NIAID and Novartis Vaccines signed an RCA to analyze the immune responses to MF59-adjuvanted influenza vaccine, Fluad. NIAID principal investigator: Gary J. Nabel, M.D., Ph.D.
NIAID and the University of North Carolina signed an RCA to analyze the therapeutic activity and immune responses of HIV-neutralizing antibodies. NIAID principal investigator: Gary J. Nabel, M.D., Ph.D.
NIAID and Nature Technology Corporation signed an RCA to optimize production methods for plasmid DNA vaccines. NIAID principal investigator: Richard Schwartz, Ph.D.
NIAID and General Electric Company signed an RCA to investigate the ability of an ultra-small superparamagnetic iron oxide (USPIO) nanoparticle to characterize an infectious disease process through visualization of macrophage uptake of the nanoparticle and accumulation in areas of inflammation and in lymph nodes. NIAID principal investigator: Peter Jahrling, Ph.D.
NIAID and Planet Biotechnology, Inc., signed an RCA to study expression of Δ-peptide-Fc fusions in plants and in vitro determination of activity. NIAID principal investigator: Peter Jahrling, Ph.D.
NIAID and Johns Hopkins University signed an RCA to study the processing and subcellular localization of PfCSP during sporozoite development in the mosquito host and sporozoite invasion of hepatocytes in vivo. NIAID principal investigator: Patrick Duffy, M.D.
NIAID and Sequella, Inc., signed an RCA to study SQ109, a novel [1,2]-diamine-based ethambutol analog for use against drug-susceptible and drug-resistant tuberculosis bacteria and to investigate Sequella’s B-SMART technology. NIAID principal investigator: Clifton E. Barry III, Ph.D.
